多發(fā)性硬化（MS）的藥物治療方案近年來發(fā)生了顯著的變化：從作用于全身副作用較大的激素類藥物發(fā)展為針對特定免疫細(xì)胞的靶向藥物；從經(jīng)sc、im或iv等非腸胃途徑給藥發(fā)展為方便的口服藥物。在諸多治療方案中，免疫調(diào)節(jié)類藥物、神經(jīng)保護(hù)類藥物和干細(xì)胞移植療法目前在臨床上占主導(dǎo)地位。隨著對MS病理學(xué)研究的發(fā)展，免疫調(diào)節(jié)類藥物已逐步被人們所認(rèn)識。按免疫調(diào)節(jié)類藥物直接靶向的免疫細(xì)胞的不同對藥物進(jìn)行分類，對藥物的作用特點(diǎn)、臨床使用情況、毒副作用等進(jìn)行綜述，同時(shí)對神經(jīng)保護(hù)劑和干細(xì)胞移植療法做簡要闡釋。

Therapeutic strategies for multiple sclerosis (MS) have radically changed in recent years: from glucocorticoids with toxicity and side-effects to targeted drugs for specific immune cells; from systematic administration, such as sc and iv injection to convenient ig administration. As we known, among these therapeutic drugs, immunomodulatory drugs, neuroprotective agents, and stem cells transplantation treatment occupy a dominant position. With the development of the research in pathology, immunomodulatory drugs have been accepted step by step. According to the immunomodulatory drugs targeting the immune cells directly, they are classified, and their function characteristics, clinical usage, and side effects are summarized. Moreover, we will also discuss the neuroprotective agent and stem cells transplantation concisely.

國家自然科學(xué)基金資助項(xiàng)目（81001656、81341088、81273817）；首都衛(wèi)生發(fā)展科研專項(xiàng)（首發(fā)2011-1001-06）；北京市優(yōu)秀人才培養(yǎng)資助項(xiàng)目（2012D005018000010）